{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:47:47Z","timestamp":1786985267827,"version":"build-2736575974"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.biopha.2025.118380","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T18:59:25Z","timestamp":1752951565000},"page":"118380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Harnessing the potential of CAR-NK cell therapy in gastrointestinal cancers: From bench to bedside"],"prefix":"10.1016","volume":"190","author":[{"given":"Ahmad","family":"Ghorbani Vanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Arghand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Ghorbaninezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Tahmasebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Taghizadeh-Anvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Safarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.biopha.2025.118380_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051124","article-title":"Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells for the multiplex targeting of bone metastases","volume":"13","author":"Grote","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1186\/s12967-023-04409-8","article-title":"CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma","volume":"21","author":"Liu","year":"2023","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118380_bib3","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"14","key":"10.1016\/j.biopha.2025.118380_bib4","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.7150\/ijbs.64630","article-title":"Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer","volume":"17","author":"Cao","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2025.118380_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21114012","article-title":"Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies","volume":"21","author":"Machlowska","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2025.118380_bib6","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.bulcan.2019.03.012","article-title":"HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer","volume":"106","author":"Wu","year":"2019","journal-title":"Bull. Cancer"},{"issue":"23","key":"10.1016\/j.biopha.2025.118380_bib7","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1158\/1078-0432.CCR-14-1071","article-title":"Ramucirumab: successfully targeting angiogenesis in gastric cancer","volume":"20","author":"Javle","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118380_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)00138-8","article-title":"Apatinib in treatment of refractory gastric cancer","volume":"17","author":"Brower","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9754","key":"10.1016\/j.biopha.2025.118380_bib9","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/S0140-6736(10)62125-3","article-title":"Trastuzumab for gastric cancer treatment","volume":"376","author":"Fujita","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biopha.2025.118380_bib10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"24","key":"10.1016\/j.biopha.2025.118380_bib11","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.biopha.2025.118380_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12032-023-02019-4","article-title":"CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies","volume":"40","author":"Faeq","year":"2023","journal-title":"Med. Oncol. (North. Lond. Engl.)"},{"issue":"5","key":"10.1016\/j.biopha.2025.118380_bib13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12015-019-09901-7","article-title":"Solid tumors challenges and new insights of CAR T cell engineering","volume":"15","author":"Tahmasebi","year":"2019","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.biopha.2025.118380_bib14","series-title":"Cancer Treatment: An Interdisciplinary Approach","first-page":"117","article-title":"Recent innovative approaches to intensify the efficacy and safety of CAR-T cell therapy in cancers","author":"Tahmasebi","year":"2023"},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","article-title":"CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy","volume":"23","author":"Hadiloo","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"10","key":"10.1016\/j.biopha.2025.118380_bib16","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jtct.2022.06.025","article-title":"The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells","volume":"28","author":"Moscarelli","year":"2022","journal-title":"Transplant. Cell. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.118380_bib17","first-page":"2823","article-title":"Development of c\u2011MET\u2011specific chimeric antigen receptor\u2011engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells","volume":"20","author":"Liu","year":"2019","journal-title":"Mol. Med. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2025.118380_bib18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ymthe.2017.12.012","article-title":"Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma","volume":"26","author":"Yu","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2025.118380_bib19","article-title":"Breaking barriers: CAR-NK cell therapy breakthroughs in female-related cancers","volume":"187","author":"Ahmad","year":"2025","journal-title":"Biomed. Pharmacother. = Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118380_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003050","article-title":"Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors","volume":"9","author":"Jan","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-020-00998-9","article-title":"Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy","volume":"13","author":"Yilmaz","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.118380_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.biopha.2025.118380_bib24","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1172\/JCI129338","article-title":"Killers 2.0: NK cell therapies at the forefront of cancer control","volume":"129","author":"Hodgins","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.biopha.2025.118380_bib25","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","article-title":"Regulation of human NK-cell cytokine and chemokine production by target cell recognition","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118380_bib26","article-title":"Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma","volume":"15","author":"Lin","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118380_bib27","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3389\/fimmu.2019.02278","article-title":"NK cell metabolism and tumor microenvironment","volume":"10","author":"Terr\u00e9n","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118380_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cyto.2019.02.001","article-title":"The role of cytokines in the regulation of NK cells in the tumor environment","volume":"117","author":"Konjevi\u0107","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2025.118380_bib29","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3389\/fimmu.2018.01859","article-title":"Prostaglandin E2 secreted by thyroid cancer cells contributes to immune escape through the suppression of natural killer (NK) cell cytotoxicity and NK cell differentiation","volume":"9","author":"Park","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118380_bib30","series-title":"Handbook of Cancer and Immunology","first-page":"1","article-title":"Pro-tumorigenic and Anti-tumorigenic Roles of Pro-inflammatory Cytokines in Cancer","author":"Tahmasebi","year":"2022"},{"issue":"4","key":"10.1016\/j.biopha.2025.118380_bib31","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/JLB.5MA0122-467R","article-title":"CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo","volume":"112","author":"Liu","year":"2022","journal-title":"J. Leukoc. Biol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118380_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24109038","article-title":"Next generation CD44v6-specific CAR-NK cells effective against triple negative breast cancer","volume":"24","author":"Raftery","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118380_bib33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.118380_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.901","article-title":"Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Clin. Transl. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118380_bib35","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.7150\/ijbs.88539","article-title":"NK-92MI cells engineered with anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer","volume":"20","author":"Li","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2054105","article-title":"STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer","volume":"11","author":"Da","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2025.118380_bib37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2020.07.016","article-title":"Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment","volume":"326","author":"Lee","year":"2020","journal-title":"J. Control Release"},{"issue":"11","key":"10.1016\/j.biopha.2025.118380_bib38","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.21873\/anticanres.13796","article-title":"Robo1-specific CAR-NK immunotherapy enhances efficacy of (125)I seed brachytherapy in an orthotopic mouse model of human pancreatic carcinoma","volume":"39","author":"Xia","year":"2019","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2025.118380_bib39","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"issue":"283","key":"10.1016\/j.biopha.2025.118380_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa4306","article-title":"STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade","volume":"7","author":"Fu","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"45","key":"10.1016\/j.biopha.2025.118380_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaz2738","article-title":"NK cells mediate clearance of CD8(+) T cell-resistant tumors in response to STING agonists","volume":"5","author":"Nicolai","year":"2020","journal-title":"Sci. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118380_bib42","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","article-title":"Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response","volume":"49","author":"Marcus","year":"2018","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biopha.2025.118380_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001998","article-title":"First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G","volume":"9","author":"Anna","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2025.118380_bib44","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.4049\/jimmunol.1700737","article-title":"Human M2 Macrophages Limit NK Cell Effector Functions through Secretion of TGF-\u03b2 and Engagement of CD85j","volume":"200","author":"Nu\u00f1ez","year":"2018","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118380_bib45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.humimm.2012.12.005","article-title":"NK cytolysis is dependent on the proportion of HLA-G expression","volume":"74","author":"Chen","year":"2013","journal-title":"Hum. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/immu.200390015","article-title":"Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation","volume":"33","author":"Contini","year":"2003","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118380_bib47","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/eji.201142179","article-title":"Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor","volume":"42","author":"Balsamo","year":"2012","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1250050","article-title":"Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G","volume":"6","author":"Kailayangiri","year":"2017","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.biopha.2025.118380_bib49","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.4049\/jimmunol.168.9.4772","article-title":"A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape","volume":"168","author":"Wiendl","year":"2002","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118380_bib50","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in cd19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118380_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056760","article-title":"Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery","volume":"8","author":"Gallmeier","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.biopha.2025.118380_bib52","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.3892\/mmr.2014.2504","article-title":"Death receptor 5 expression is inversely correlated with prostate cancer progression","volume":"10","author":"Hernandez-Cueto","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2025.118380_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.565306","article-title":"Cancer-associated fibroblast density, prognostic characteristics, and recurrence in head and neck squamous cell carcinoma: a meta-analysis","volume":"10","author":"Knops","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118380_bib54","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","article-title":"IL1-Induced JAK\/STAT signaling is antagonized by TGF\u03b2 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma","volume":"9","author":"Biffi","year":"2019","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.biopha.2025.118380_bib55","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.canlet.2011.12.020","article-title":"Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO","volume":"318","author":"Li","year":"2012","journal-title":"Cancer Lett."},{"issue":"6005","key":"10.1016\/j.biopha.2025.118380_bib56","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1126\/science.1195300","article-title":"Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha","volume":"330","author":"Kraman","year":"2010","journal-title":"Science"},{"issue":"50","key":"10.1016\/j.biopha.2025.118380_bib57","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"14","key":"10.1016\/j.biopha.2025.118380_bib58","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-14-3041","article-title":"Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells","volume":"75","author":"Lo","year":"2015","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.118380_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006130","article-title":"Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2025.118380_bib60","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.onc.1203426","article-title":"Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer","volume":"19","author":"Gu","year":"2000","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.biopha.2025.118380_bib61","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/01.MP.0000086072.56290.FB","article-title":"Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray","volume":"16","author":"Maitra","year":"2003","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118380_bib62","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/01.mpa.0000173459.81193.4d","article-title":"Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer","volume":"31","author":"Wente","year":"2005","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.biopha.2025.118380_bib63","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","article-title":"Off-the-shelf prostate stem cell antigen-directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer","volume":"162","author":"Teng","year":"2022","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.biopha.2025.118380_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101611","article-title":"Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method","volume":"11","author":"Flieswasser","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.biopha.2025.118380_bib65","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000446569","article-title":"CD70 expression and its correlation with clinicopathological variables in squamous cell carcinoma of the head and neck","volume":"83","author":"De Meulenaere","year":"2016","journal-title":"Pathobiology"},{"issue":"4","key":"10.1016\/j.biopha.2025.118380_bib66","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00428-019-02565-1","article-title":"CD70 expression in tumor-associated fibroblasts predicts worse survival in colorectal cancer patients","volume":"475","author":"Inoue","year":"2019","journal-title":"Virchows Arch."},{"issue":"7","key":"10.1016\/j.biopha.2025.118380_bib67","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440167","article-title":"Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation","volume":"7","author":"Jacobs","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118380_bib69","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00262-011-1067-6","article-title":"Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function","volume":"60","author":"Moustaki","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib70","article-title":"Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells","volume":"32","author":"Yoon","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.biopha.2025.118380_bib71","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1186\/s12885-015-1657-3","article-title":"Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy","volume":"15","author":"Yu","year":"2015","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2025.118380_bib72","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1189\/jlb.1106678","article-title":"Slit-2\/Robo-1 modulates the CXCL12\/CXCR4-induced chemotaxis of T cells","volume":"82","author":"Prasad","year":"2007","journal-title":"J. Leukoc. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118380_bib73","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3892\/or.2013.2516","article-title":"The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer","volume":"30","author":"He","year":"2013","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2025.118380_bib74","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/jcrt.JCRT_190_20","article-title":"Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver metastasis","volume":"16","author":"Li","year":"2020","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.biopha.2025.118380_bib75","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2147\/CMAR.S253565","article-title":"DNAM1 and 2B4 costimulatory domains enhance the cytotoxicity of anti-GPC3 chimeric antigen receptor-modified natural killer cells against hepatocellular cancer cells in vitro","volume":"12","author":"Huang","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib76","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10238-025-01711-1","article-title":"Macrophage polarization in hepatocellular carcinoma: a lncRNA-centric perspective on tumor progression and metastasis","volume":"25","author":"Ghorbani Vanan","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.biopha.2025.118380_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155928","article-title":"Harnessing immunotherapy for hepatocellular carcinoma: principles and emerging promises","volume":"269","author":"Miri","year":"2025","journal-title":"Pathol. Res. Pract."},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib78","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1038\/s41467-020-18444-2","article-title":"Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma","volume":"11","author":"Tseng","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib79","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1080\/21655979.2021.1950261","article-title":"Optimization of GPC3-specific chimeric antigen receptor structure and its effect on killing hepatocellular carcinoma cells","volume":"12","author":"Zhao","year":"2021","journal-title":"Bioengineered"},{"issue":"4","key":"10.1016\/j.biopha.2025.118380_bib80","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1078-0432.CCR-12-2616","article-title":"First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2025.118380_bib81","doi-asserted-by":"crossref","first-page":"6210","DOI":"10.4049\/jimmunol.167.11.6210","article-title":"2B4 (CD244)-mediated activation of cytotoxicity and IFN-gamma release in human NK cells involves distinct pathways","volume":"167","author":"Chuang","year":"2001","journal-title":"J. Immunol."},{"issue":"22","key":"10.1016\/j.biopha.2025.118380_bib82","doi-asserted-by":"crossref","first-page":"12718","DOI":"10.1073\/pnas.2135113100","article-title":"GF. Hepatocyte growth factor\/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation","volume":"100","author":"Zhang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.biopha.2025.118380_bib83","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/jcph.148","article-title":"Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors","volume":"53","author":"Xin","year":"2013","journal-title":"J. Clin. Pharmacol."},{"issue":"13","key":"10.1016\/j.biopha.2025.118380_bib84","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1128\/MCB.05160-11","article-title":"Characterization of basigin isoforms and the inhibitory function of basigin-3 in human hepatocellular carcinoma proliferation and invasion","volume":"31","author":"Liao","year":"2011","journal-title":"Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118380_bib85","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2559.2009.03280.x","article-title":"HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection","volume":"54","author":"Li","year":"2009","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.biopha.2025.118380_bib86","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1023\/A:1006538200886","article-title":"Proteolysis of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by matrix metalloproteinases","volume":"16","author":"Kelly","year":"1998","journal-title":"Clin. Exp. Metastas."},{"issue":"3","key":"10.1016\/j.biopha.2025.118380_bib87","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1006\/gyno.2001.6294","article-title":"Localization of matrix metalloproteinases on endometrial cancer cell invasion in vitro","volume":"82","author":"Park","year":"2001","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118380_bib88","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00262-017-1959-1","article-title":"Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-\u03b2R II and NKG2D","volume":"66","author":"Wang","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.biopha.2025.118380_bib89","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.intimp.2013.06.003","article-title":"Blocking transforming growth factor-\u03b2 signaling pathway augments antitumor effect of adoptive NK-92 cell therapy","volume":"17","author":"Yang","year":"2013","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118380_bib90","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2468-1253(20)30007-8","article-title":"The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Naghavi","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118380_bib91","article-title":"Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma","volume":"15","author":"Lin","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib92","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10238-025-01730-y","article-title":"CCAT2 role in gastrointestinal cancer progression and metastasis: a novel target for therapeutic strategies","volume":"25","author":"Vanan","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"11","key":"10.1016\/j.biopha.2025.118380_bib93","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/ijc.35365","article-title":"DCLK1 in gastrointestinal cancer: a driver of tumor progression and a promising therapeutic target","volume":"156","author":"Vanan","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118380_bib94","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1016\/j.biopha.2025.118380_bib95","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1159\/000447859","article-title":"B7-H3 overexpression predicts poor survival of cancer patients: a meta-analysis","volume":"39","author":"Ye","year":"2016","journal-title":"Cell Physiol. Biochem."},{"issue":"17","key":"10.1016\/j.biopha.2025.118380_bib96","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1158\/1078-0432.CCR-16-3107","article-title":"B7-H3 expression in NSCLC and Its association with B7-H4, PD-L1 and tumor-infiltrating lymphocytes","volume":"23","author":"Altan","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2025.118380_bib97","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/cells10051020","article-title":"In vitro evaluation of CD276-CAR NK-92 functionality, migration and invasion potential in the presence of immune inhibitory factors of the tumor microenvironment","volume":"10","author":"Grote","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000450","article-title":"PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations","volume":"8","author":"Fabian","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"261","key":"10.1016\/j.biopha.2025.118380_bib99","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2025.118380_bib100","volume":"11","author":"Organization","year":"2023","journal-title":"Colorectal cancer WHO"},{"issue":"10207","key":"10.1016\/j.biopha.2025.118380_bib101","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.biopha.2025.118380_bib102","first-page":"662","article-title":"The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer","volume":"20","author":"Wang","year":"2023","journal-title":"Cancer Biol. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118380_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12051129","article-title":"Regulation of the function and expression of EpCAM","volume":"12","author":"Xiao","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118380_bib104","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4263520","article-title":"Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models","volume":"2018","author":"Zhang","year":"2018","journal-title":"J. Immunol. Res."},{"issue":"12","key":"10.1016\/j.biopha.2025.118380_bib105","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018100928","article-title":"3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids","volume":"38","author":"Schnalzger","year":"2019","journal-title":"EMBO J."},{"issue":"9","key":"10.1016\/j.biopha.2025.118380_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14093189","article-title":"Carcinoembryonic antigen (CEA): origin, role in oncology, and concentrations in serum and peritoneal fluid","volume":"14","author":"Niedzielska","year":"2025","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118380_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16020388","article-title":"Next-generation CEA-CAR-NK-92 cells against solid tumors: overcoming tumor microenvironment challenges in colorectal cancer","volume":"16","author":"Franz\u00e9n","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2025.118380_bib108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12865-018-0262-z","article-title":"Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells","volume":"19","author":"Shiozawa","year":"2018","journal-title":"BMC Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118380_bib109","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2025.118380_bib110","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s11010-022-04568-0","article-title":"Challenges of chimeric antigen receptor-T\/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies","volume":"478","author":"Wang","year":"2023","journal-title":"Mol. Cell. Biochem."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:59:27Z","timestamp":1755737967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225005748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":110,"alternative-id":["S0753332225005748"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118380","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing the potential of CAR-NK cell therapy in gastrointestinal cancers: From bench to bedside","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118380"}}